卡培他滨联合贝伐珠单抗治疗晚期结直肠癌的效果

Effect of Capecitabine Combined with Bevacizumab in the Treatment of Advanced Colorectal Cancer

目的:探讨卡培他滨联合贝伐珠单抗治疗晚期结直肠癌的效果。方法:选择惠州市第三人民医院2018年1月-2019年12月收治的60例晚期结直肠癌患者作为研究对象。按随机数字表法将其分为对照组和观察组,每组30例。对照组给予卡培他滨片,观察组给予卡培他滨片联合贝伐珠单抗注射液。比较两组治疗效果,治疗前后肿瘤标志物及血管内皮生长因子(VEGF)、相关蛋白表达及安全性。结果:观察组疾病控制率为90.00%,高于对照组的66.67%(P<0.05)。治疗后,观察组糖类抗原199(CA199)、CA125、癌胚抗原(CEA)、VEGF、CA242水平均低于对照组(P<0.05)。治疗后,观察组p53蛋白、B淋巴细胞瘤2(Bcl-2)蛋白阳性率均低于对照组,Bax阳性率高于对照组(P<0.05)。两组不良反应发生率比较差异无统计学意义(P>0.05)。结论:相较于单独卡培他滨治疗晚期结直肠癌,其联合贝伐珠单抗可有效降低血清肿瘤标志物水平和调节相关蛋白表达,提高治疗效果,且不会增加毒副反应,安全性较好。

Objective:To investigate the effect of Capecitabine combined with Bevacizumab in the treatment of advanced colorectal cancer.Method:A total of 60 patients with advanced colorectal cancer treated in Huizhou Third People’s Hospital from January 2018 to December 2019 were selected as the research objects.They were divided into control group and observation group according to the random number table method,with 30 cases in each group.The control group was given Capecitabine Tablets,and the observation group was given Capecitabine Tablets combined with Bevacizumab Injection.The therapeutic effect,tumor markers,vascular endothelial growth factor (VEGF),related protein expression and after treatment and safety of the two groups were compared.Result:The disease control rate in the observation group was 90.00%,which was higher than 66.67% in the control group (P<0.05).After treatment,the levels of carbohydrate antigen 199 (CA199),CA125,carcinoembryonic antigen (CEA),VEGF and CA242 in the observation group were lower than those in the control group (P<0.05).After treatment,the positive rates of p53 protein and B-lymphoma 2 (Bcl-2) protein in the observation group were lower than those in the control group,and the positive rate of Bax was higher than that in the control group (P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05).Conclusion:Compared with Capecitabine alone in the treatment of advanced colorectal cancer,it combined with Bevacizumab can effectively reduce the level of serum tumor markers and regulate the expression of related proteins,improve the treatment effect,and will not increase toxic and side effects,with better safety.